-
UCB Announces U.S. FDA Approval for Zilbrysq (zilucoplan) Autoinjector Self-administration for Adults Living with Generalized Myasthenia Gravis
Brussels, Belgium and Atlanta, Georgia – October 16, 2026 – UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the first self-administered… Source: Read More
-
A Breakthrough in Lupus Care: New Phase 3 Results for Dapirolizumab Pegol
NASDAQ: $BIIB Advancements in Lupus Treatment The landscape of treatment for Systemic Lupus Erythematosus (SLE) is evolving. UCB and Biogen have recently announced the publication of results from their Phase 3 clinical study of dapirolizumab pegol (DZP) in The Lancet, marking a significant milestone in the quest for more effective therapies for this complex autoimmune…